Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medicine
Zenas BioPharma announced positive Phase 3 INDIGO trial results for obexelimab in treating Immunoglobulin G4-Related Disease (IgG4-RD). The trial met its primary and all key secondary endpoints with statistically significant reductions in disease flare risk, glucocorticoid use, and related toxicities. Obexelimab demonstrated a favorable safety prof…